Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative bioavailability and food-effect study of MK-3682A fixed-dose combination formulations in healthy adults
NL-OMON57828Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of uprifosbuvir, grazoprevir and verubecestat in hepatitis C virus infection (5 arms), sponsored by Merck & Co. Primary endpoints: Relative bioavailability pharmacokinetics and Food-effect pharmacokinetics. Started Dec 2014; status: completed.
02
Drugs
uprifosbuvirgrazoprevirverubecestat
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON57828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57828.